INTRODUCTION
Colon cancer, one of the common malignant tumors of the digestive tract, occurs at the junction between the rectum and the sigmoid colon [1, 2] . It is more common in males than in females and affects mostly people in the age group of 50-60 year [1, 2] . Studies have revealed that colon cancer progression involves several mechanisms such as alteration of the apoptotic pathway and mutation of cell cycle components [3] [4] [5] [6] . It has also been observed that activation of infiltrating immune cells and immunosuppressive pathways play vital role in the development and progression of colon cancer [7] . Treatment strategies for colon cancer include chemotherapy, radiotherapy and surgical intervention [7] .
Ludartin is a sesquiterpene lactone with cytotoxic, antitumor and anti-bactericidal properties [8] . Synthetic analogs of ludartin have also shown promising pharmaceutical activities [9] . In view of the antitumor properties of ludartin, the present study was designed to investigate its effect on colon tumor growth in s mice model. Selective delivery of 5-fluorouracil into tumor cells is achieved by the use of capecitabine [10] . Capecitabine, used alone or in combination with other drugs has been investigated for the treatment of gastric cancers [10] . High doses of capecitabine cause result in some unwanted side effects such as drug resistance, diarrhoea and lymphopenia, but at lower doses, the drug is effective for cancer treatment [10] .
The present study investigates the effect of combined treatment with ludartinin and capecitabine on colon tumor growth in a mice model of colon cancer.
EXPERIMENTAL Animals
Twenty five female nude BALB/c mice, aged 7 -8 weeks, were supplied by the Animal Experiment Centre of Beijing, China. The mice were housed under conditions free from pathogens at room temperature, 55 % humidity and circadian 12 h light/12 h dark rhythm. All the animals were allowed free access to CLEA rodent diet (CA-1) and tap water.
Chemicals and cell culture
Ludartin amd azoxymethane (AOM) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Capecitabine was supplied by Roche Pharmaceutical Company (Nutley, NJ, USA). Dextran sulfate sodium (DSS; cat. no. 160110) was product of MP Biomedicals, LLC (Aurora, OH). HCT-116 cancer cell line was obtained from Cell Resource Centre for Biomedical Research, Aging and Cancer, Tohoku University, Japan. The cells were cultured in RPMI-1640 medium at 37 o C under an atmosphere of 5 % CO 2 and 95 % air. The medium was supplemented with 10 % NBS containing penicillin (100 U/mL) and streptomycin (100 µg/mL).
Animal experiment design
The experimental procedures used in the animal studies were performed in accordance with the international Guide for the Care and Use of Laboratory Animals [11] . Approval for the study was obtained from the Ethics Committee of Hebei United University for the use of animals. Colon cancer was induced in mice by administration of AOM and DSS. The mice were divided into five groups of 5 animals each. Four groups received AOM and DSS intraperitoneally and the normal control was given saline only. The AOM was given through intraperitoneal injection at a dose of 10 mg/kg body weight. An aqueous solution of DSS [(1.5 g of DSS was dissolved in 100 mL of water to get 1.5 % (w/v)] was given to the mice orally one week after AOM injection. Mice in the capecitabine, ludartin and combination treatment groups were administered 200 mg/kg capecitabine, 10 µM ludartin, and 100 mg/kg capeitabine plus 10 µM ludartin, respectively daily by gavage for one month. At the end of the treatments, the mice were sacrificed under 10 % chloral hydrate (3 mg/kg) anaesthesia administered intraperitoneally.
Analysis of tumor growth and side effects
During the study, mice in all groups were weighed and examined carefully to record changes in body weight and physical appearance. Blood samples were collected for determination of white blood cell (WBC) count.
Real-time polymerase chain reaction (RT-PCR) analysis
After the mice were sacrificed, the colon tumour was excised and stored under liquid nitrogen till further analysis. Total RNA was extracted from the colon tumor tissue using TRIzol reagent (Invitrogen, USA). Reverse transcription of the extracted RNA was performed using oligo (dT) primers. Analysis of the mRNA expression was carried out by quantitative real time reverse transcription-PCR. The primers used for reverse transcription of VEGF were 5'-GAGCCTTGCC TTGCTGCTCTAC for forward and 5'-CACCAGGGTCTCGATTGGATG for backward. 
Analysis of VEGF and CD31 in colon cancer tissues
Colon tumor tissues were fixed in 10 % buffered formalin phosphate. The fixed tissues were embedded in paraffin and subsequently sliced into thin sections for immunohistochemical examination using PV-9000 kit (Beijing Zhongshan Goldenbridge Biotechnology Company, Beijing, China). The tissue sections were de-waxed in boiling xylene and then treated with VEGF rabbit anti-human monoclonal antibody (Fuzhou Maixin Company, China), and CD31 rat anti-mouse monoclonal antibody (Dako, Japan) at 1 : 100 dilution. The treatment was performed for 3 minutes under pressure in citrate buffer (pH 6.0). Expression of VEGF was indicated by presence of stained cytoplasm VEGF [12] .
Determination of micro-vessel density
Micro-vessel density was determined immunohistochemically [13] , using antibodies against endothelial marker CD31. Initially, the sections were examined at a magnification of x 40 and x 100, to localize regions of high neovascularization. Endothelial cells that stained yellow-brown were taken as micro-vessel. The selected microvessels were further examined at a high magnification (x 200) to determine the micro-vessel density (MVD) count, and the images were captured with Zeiss fluorescence microscope (Zeiss Inc.) equipped with an Olympus N547 digital camera (Olympus).
Statistical analysis
Results are presented as mean ± S.E.M. Analysis of data on survival was performed using Kaplan Meier analysis. ANOVA and StudentNewman-Keuls tests were also used for data analysis. SPSS 17.0 software package was used for all statistical analyses. Values of p < 0.05 were considered statistically significant.
RESULTS

Effect of capecitabine and ludartin on tumour growth
In the control group, tumour growth was prompt and after 6 weeks, all mice had large tumour sizes (Figure 1 ). Tumour growth was delayed markedly in the capecitabine-treated group of mice for 4 weeks (p < 0.02; Figure 1 ). Treatment with ludartin exhibited tumor growth-delaying effect similar to that of capecitabine. Combination of capecitabine and ludartin brought about significant inhibition of tumour growth, so much so that there was no tumour growth was observed 6 weeks after treatment (p < 0.05; Figure 1 ). 
Effect of capecitabine and ludartin on WBC count
Mice in the control, untreated group showed various symptoms such as weight reduction, skin discoloration and leukopenia during the 6-week study. However, no such symptoms were observed in the mice treated with capecitabine, ludartin or combination of capecitabine and ludartin.
After two weeks of tumour establishment, WBC count was same in all the groups of mice. No significant changes in WBC count were seen in the capecitabine, ludartin or combination (capecitabine and ludartin) treatment groups. On the other hand, there were significant decreases in WBC count in the control group within two weeks (p < 0.05; Figure 2 ). 
Effect of capecitabine and ludartin on mice survival
Mice in the control group had median survival time of 38 days. The median survival times of mice in capecitabine and ludartin treatment groups were 49 and 50 days, respectively (p < 0.02). The median survival time of mice in the combination treatment group was 55 days (p < 0.02).
Effect of capecitabine and ludartin on VEGF expression
The expression of VEGF gene was significantly higher in the untreated control mice group, when compared to normal healthy mice (Figure 3) . However, VEGF expression was significantly lower in the capecitabine and ludartin treatment groups, relative to the control group. Expression of VEGF in the combination (capecitabine and ludartin) treatment group was significantly lower when compared to the capecitabine and ludartin treatment groups (p > 0.05; Figure 3 ). 
Effect of capecitabine and ludartin on colon tissue histopathology of mice
Histopathological examination of tissues from the mice of control group showed markedly higher count of microvessels, when compared to the normal mice (Figure 4) . Microvessel count was lower in the capecitabine and ludartin treatment groups of mice, relative to the control group. Combination treatment produced even lower micro-vessel counts in the colon tumour tissues, when compared to the capecitabine or ludartin treated mice (Figure 4 ).
DISCUSSION
Investigation of the effect of capecitabine and ludartin on colon tumour growth either alone or in combination revealed that combination of capecitabine and ludartin was an effective treatment regimen. The combination of capecitabine and ludartin inhibited colon tumor growth and angiogenesis. Therapeutic strategies using known drugs in combination with phytochemicals have been found effective for treatment of various disorders, and are highly encouraged [14, 15] . In the present study, the effect of capecitabine and ludartin separately or in combination on colon tumor angiogenesis in a mice model was investigated. The results showed that tumor growth in control mice was prompt, resulting in large tumour size in all the animals within one month.
However, capecitabine treatment caused marked delay in tumour growth for 21 days. Ludartin treatment also exhibited tumour growth-inhibiting. However the most effective inhibition of tumour growth was produced by the combination of two drugs, which resulted in absence of tumor growth for one month. At lower doses, capecitabine is efficient for cancer treatment because of its specificity for tumour cells [10] . Mice in the control group showed various symptoms such as weight reduction, skin discoloration and leukopenia, all of which were reversed by capecitabine, ludartin or combination (capecitabine and ludartin) treatment.
VEGF plays an important role in the progression of tumour angiogenesis; its expression is a characteristic of angiogenesis [16, 17] . Studies have shown that higher expression of VEGF in tumor cells is associated with the development of drug resistance [18] [19] [20] . The present study showed that in the colon tumor cells of control, untreated group, the expression of VEGF gene was markedly higher than that in normal, healthy control mice. However, the expression of VEGF in the colon tumor-bearing mice was markedly reduced on treatment with combination of capecitabine and ludartin. Higher micro-vessel density in tumour cells is considered to be the characteristic feature of angiogenesis [21] . The expression of VEGF and micro-vessel count are directly related [22] . In the present study, results from histopathological examination of tumour tissues of the untreated, control mice showed markedly higher count of micro-vessels than corresponding values for healthy control mice. Treatment with combination of capecitabine and ludartin led to a significant decrease in the count of micro-vessels in the tumour tissues, relative to the capecitabine or ludartin treatment when used alone.
CONCLUSION
The findings of this study show that the combination of capecitabine and ludartin inhibits colon tumour growth and angiogenesis in mice via suppression of VEGF expression. Thus, capecitabine and ludartin combination has a potential for development into a suitable medication for the treatment of colon cancer.
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